A study published in The Lancet Psychiatry has linked GLP-1 medications to a reduced need for acute psychiatric care among patients who have both schizophrenia and type 2 diabetes, according to the Science Media Centre, which gathered expert reaction to the findings on Wednesday.
The research examined whether the drugs, widely used to treat diabetes and support weight loss, might also be connected to better mental health outcomes in this patient group. The Science Media Centre collected comments from several UK clinicians and researchers, who described the results as interesting and potentially important while cautioning that the study design cannot show cause and effect.
Why it matters
People living with schizophrenia face substantial inequalities in their physical health, a point raised by Dr Jon van Niekerk, Chair of the Faculty of General Adult Psychiatry at the Royal College of Psychiatrists. The possibility that medicines prescribed to improve metabolic health might also be associated with fewer psychiatric crises is therefore worth serious attention, he said.
The study's scale and its use of routinely collected clinical data were strengths, according to van Niekerk. He also highlighted that the researchers compared GLP-1 users with patients taking other diabetes medications, an approach that helps reduce some sources of bias.
The outcomes the study looked at — psychiatric admissions and emergency mental health care — are clinically meaningful, van Niekerk said. Even so, he stressed that the research cannot establish that GLP-1 medications directly ease psychiatric symptoms or prevent relapse.
What the study can and cannot show
Van Niekerk raised a central question about the analysis: whether the researchers adequately accounted for differences in how severely ill patients were, what antipsychotics they were prescribed, and how engaged they were with healthcare.
He offered a concrete example. Patients already stabilised on clozapine or other antipsychotics known to cause significant metabolic problems may be more likely to be offered GLP-1 treatment. But their underlying psychiatric stability, and their risk of being admitted to hospital, could differ greatly from other patients. Those factors are hard to fully control for in observational research, he said.
One result the experts found particularly intriguing was that the association held among people who did not lose weight. According to van Niekerk, this raises questions about mechanisms that may operate independently of weight reduction, though it does not prove a direct effect on schizophrenia itself.
He noted that the findings fit with a growing body of observational research pointing to possible psychiatric benefits from some GLP-1 medications. Randomised evidence, however, has not yet shown a clear improvement in psychotic symptoms. Van Niekerk drew a distinction between patients needing fewer acute psychiatric services and the underlying illness actually improving.
His overall assessment was that the work is promising and strengthens the argument for further investigation, ideally through randomised trials. It also underlines the value of treating physical and mental health together. Still, he said it would be premature to view GLP-1 medications as treatments for schizophrenia or to change psychiatric prescribing based on these results alone.
Dr Riccardo De Giorgi, a senior clinical researcher and honorary consultant in general adult psychiatry at the University of Oxford, called it a large, well-conducted observational study. He said both the paper and its press release were appropriately careful in how they framed the results.
De Giorgi pointed to the NeuroBlu dataset used in the research, which allowed unusually detailed adjustment for psychiatric treatment. That included antipsychotic use, metabolic-risk category and route of administration — factors he said matter because they can be obvious sources of confounding.
In his reading, the headline results are interesting but more nuanced than a simple protective association. The links were clearest among younger people and those taking antipsychotics, and were less consistent across several other subgroups. He also urged caution over the weight-loss reporting: the association was strongest in people who lost weight and persisted with stable weight in some comparisons, but was not consistent in those who gained weight. That leaves open the possibility of benefits beyond weight loss, he said, while still falling short of demonstrating a weight-independent psychiatric effect.
De Giorgi identified residual confounding as the main limitation, as is typical with this kind of study design. Prescribing GLP-1s may single out patients who differ in their healthcare engagement or clinical profile in ways that electronic health record adjustment cannot capture, he said.
His conclusion was that the findings extend existing evidence by providing another signal that GLP-1 treatment may have benefits beyond metabolic health for people with schizophrenia and diabetes. They cannot yet show that the drugs prevent relapse or act as psychiatric treatments, and that question now calls for a randomised controlled trial.
A possible route through antipsychotic side effects
Prof Joseph Firth, Professor of Psychology and Mental Health at the University of Manchester, offered a different angle on why the association might exist.
He described increased appetite and reduced feelings of fullness as among the most striking and overlooked side effects of antipsychotic medications. For some patients, he said, this can make sticking to a healthy diet or managing bodyweight feel nearly impossible. That in turn can lead people to stop taking their medication on their own — a common factor preceding relapse and hospitalisation.
GLP-1 receptor agonists appear to regulate appetite and satiety pathways particularly quickly and powerfully, Firth said, which could offset most of the downsides of antipsychotics in that one area. It therefore makes sense, in his view, that using these drugs in an evidence-based way could help address some of the most damaging physical side effects of antipsychotics and, by doing so, help people stay on their psychiatric treatment. That could mean less need for acute care or hospitalisation down the line.
Firth said the main limitation of this emerging field is that the studies so far are observational, which rules out causal conclusions. Even so, he said the work opens the door to many theories and further research. He identified two priorities: establishing whether and how far the findings hold in other psychiatric populations, and pinning down the key driving factors — whether medication adherence or something else — so these treatments can be best combined with other pharmacological and behavioural strategies to improve both physical and mental health.
The Science Media Centre also listed Dr Sameer Jauhar, Clinical Associate Professor in Affective Disorders, among the experts commenting, though the available material does not include his remarks.
What to watch: whether researchers follow up with randomised trials that can test whether GLP-1 drugs genuinely reduce relapse in schizophrenia, rather than just the use of acute services.
